|Bid||73.64 x 1300|
|Ask||73.98 x 1800|
|Day's range||72.75 - 74.90|
|52-week range||56.81 - 80.74|
|Beta (3Y monthly)||0.88|
|PE ratio (TTM)||50.15|
|Earnings date||16 Apr 2019 - 22 Apr 2019|
|Forward dividend & yield||1.28 (1.60%)|
|1y target est||82.78|
Jeff Jonas of Gabelli talks about a closed-end fund that invests in the health-care and consumer staples sectors.
U.S. stocks headed lower on Wednesday, as a selloff in healthcare stocks extended for a second day, overshadowing a rally in chipmakers led by Qualcomm. Medical device maker Abbott Laboratories Inc fell 3.8%, despite quarterly results beating estimates. UnitedHealth Group Inc, Pfizer Inc and Merck & Co fell more than 2% and were the biggest drags on the broader S&P 500 index.
(Reuters) - Abbott Laboratories Inc reported higher-than-expected first-quarter profit and sales on Wednesday on surging sales of its Freestyle Libre glucose monitoring device and as more of its heart ...
Investing.com - UnitedHealth Group fell deeper into the red Wednesday as analysts turned bearish on the stock in the wake of its CEO's warning on political risk.
Abbott (ABT) delivered earnings and revenue surprises of 3.28% and 0.91%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Shares of Abbott Laboratories gained 0.8% in premarket trade Wednesday, after the health-care company reported first-quarter earnings that beat expectations, sales that were slightly above and full-year profit guidance that was in line. Net income rose to $1.13 billion, or 38 cents a share, from $1.05 billion, or 23 cents a share, in the year-ago period. Excluding non-recurring items, adjusted EPS rose to 63 cents from 59 cents, above the FactSet consensus of 61 cents. Sales increased 2% to $7.54 billion, topping the FactSet consensus of $7.48 billion. Medical device sales rose 5.5% to $2.90 billion, above the FactSet consensus of $2.88 billion; diagnostic sales edged up 0.2% to $1.84 billion, matching expectations; nutrition sales grew 2.0% to $1.79 billion versus expectations of $1.74 billion; and established pharmaceutical sales fell 4.9% to $992 million, missing expectations of $999.4 million. The company expects adjusted EPS of 79 cents for the second-quarter, surrounding the FactSet consensus of 80 cents, and $3.15 to $3.25 for 2019, compared with expectations of $3.21. The stock has tacked on 5.6% year to date through Tuesday, while the S&P 500 has rallied 16%.
The Abbott Park, Illinois-based company said it had profit of 38 cents per share. Earnings, adjusted for one-time gains and costs, came to 63 cents per share. The results beat Wall Street expectations. ...
Investing.com - Abbott Labs (NYSE:ABT) reported first quarter earnings that Beat analysts' expectations on Wednesday and revenue that topped forecasts.
Abbott (ABT) expects high single-digit growth in Medical Devices' sales in first-quarter 2019 and continued double-digit growth in certain sub-segments.
Global chemical giants DowDuPont Inc. and BASF SE are investing millions to ramp up production of an indigestible sugar found naturally in breast milk. Infant formula makers like Nestle SA can’t get enough of the synthetic ingredient. DuPont estimates the annual market could reach $1 billion.
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put i...
Worry over growing competition caused investors to sell shares in this leading diabetes management company, but that could be a mistake.
On closure of the acquisition deal, Brammer Bio will be integral to Thermo Fisher's (TMO) pharma services business within its Laboratory Products and Services wing.